Triumph Capital Management Regeneron Pharmaceuticals, Inc. Transaction History
Triumph Capital Management
- $270 Million
- Q4 2024
A detailed history of Triumph Capital Management transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Triumph Capital Management holds 560 shares of REGN stock, worth $399,420. This represents 0.15% of its overall portfolio holdings.
Number of Shares
560
Previous 423
32.39%
Holding current value
$399,420
Previous $444,000
10.36%
% of portfolio
0.15%
Previous 0.17%
Shares
2 transactions
Others Institutions Holding REGN
# of Institutions
1,487Shares Held
85.7MCall Options Held
1.53MPut Options Held
1.43M-
Vanguard Group Inc Valley Forge, PA9.29MShares$6.62 Billion0.12% of portfolio
-
Black Rock Inc. New York, NY8.45MShares$6.02 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY7.06MShares$5.04 Billion0.41% of portfolio
-
State Street Corp Boston, MA4.83MShares$3.45 Billion0.14% of portfolio
-
Capital International Investors Los Angeles, CA4.74MShares$3.38 Billion0.66% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $76.5B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...